{
  "chapter": "Other Hemolytic Anemias",
  "questions": [
    {
      "q_no": 1,
      "question": "A 45-year-old woman presents with a sudden onset of fatigue, jaundice, and dark urine. On examination, she has splenomegaly. Laboratory tests reveal an elevated reticulocyte count, elevated lactate dehydrogenase (LDH), and positive direct Coombs test for IgG antibodies. Which of the following is the most appropriate first-line treatment for this patient?",
      "options": {
        "A": "Splenectomy",
        "B": "Prednisone + Azathioprine",
        "C": "Prednisone + Rituximab",
        "D": "Intravenous Immunoglobulin (IVIG)"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) Prednisone + Rituximab Explanation: This patient likely has Warm Autoimmune Hemolytic Anemia . The combination of prednisone 1 mg/kg/day and Rituximab (100 mg/week for 4 weeks) is effective as it provides immediate control of hemolysis through corticosteroids while Rituximab targets the underlying B-cell-mediated process, reducing relapse rates. Management of Warm Autoimmune Hemolytic Anemia First-Line Treatment : Initiate treatment with prednisone at 1 mg/kg/day , which induces remission in approximately 50% of cases. Combine with anti-CD20 Rituximab (100 mg/week for 4 weeks) to potentially reduce relapse rates. (Option C) Alternative Therapies for Relapse/Refractoriness : Splenectomy can improve anemia and decrease reliance on other therapies by eliminating a primary site of hemolysis, but it also poses risks of sepsis and thrombosis. (Option A ruled out) Second- and Third-Line Treatments : Azathioprine (Option B ruled out) , Cyclophosphamide, Cyclosporine, Mycophenolate, Intravenous immunoglobulin (Option D ruled out) Additional Support : Erythropoietin may be used to help reduce or avoid the need for red blood cell transfusions in cases of severe anemia associated with reticulocytopenia. Management of Cold Agglutinin Disease (CAD) First-Line Treatment : Rituximab is the primary treatment for CAD, as prednisone and splenectomy are ineffective in managing this condition. Emerging Therapies : For relapses, consider B-cell receptor inhibitors such as venetoclax & ibrutinib , as well as the proteasome inhibitor bortezomib . Supportive Care : Blood transfusions may be beneficial, though donor red cells (I-positive) will have a similar survival rate to the patient’s own cells. It is essential to keep both the blood bag and the patient's extremities warm during transfusions. Reference: Harrison’s principles of internal medicine 21st edition Page: 787, 788.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Other Hemolytic Anemias"
    },
    {
      "q_no": 2,
      "question": "A 34-year-old female patient is admitted to the emergency department with a sudden onset of fever, chills, and dark urine. She recently received a blood transfusion for severe anemia due to menorrhagia. Laboratory tests reveal elevated free hemoglobin, increased lactate dehydrogenase (LDH), and decreased haptoglobin. Urinalysis shows hemoglobinuria. What is the most likely mechanism responsible for the hemolysis observed in this patient?",
      "options": {
        "A": "Mechanical shear-force associated lysis",
        "B": "Complement fixation and direct lysis",
        "C": "Membrane or hemoglobin disorder-associated lysis",
        "D": "Exogenous toxic factors"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) Complement fixation and direct lysis Explanation: The clinical symptoms of fever, chills, and dark urine, combined with a history of blood transfusion, suggest the diagnosis of intravascular hemolysis , which is mostly due to antibodies binding to incompatible red blood cells (RBCs), leading to the fixation and activation of the complement cascade . The complement cascade forms the membrane attack complex, which creates pores in the RBC membrane, causing lysis and destruction . Mechanism of hemolysis: Intravascular hemolysis directly releases Hb into the bloodstream, which can be toxic to various organ systems. Released Hb quickly dissociates into: α – β globin dimers Globin monomers Methemoglobin (MetHgb) MetHgb and globin forms (both dimers and monomers) bind to haptoglobin , a high-affinity scavenger protein produced by the liver. MetHgb can also bind to albumin, forming methemalbumin. Free heme porphyrin is cleared by the liver. Large-scale hemolysis can rapidly deplete circulating haptoglobin and hemopexin stores, leading to the presence of free Hb in the blood. Clinical features: Massive intravascular hemolysis can lead to severe complications, including: Fever Hypotension Bleeding Multiorgan system failure Death Causes of intravascular hemolysis: Mechanism Conditions Complement fixation and direct lysis (Immune-Mediated) Cold autoimmune hemolytic anemia ABO antibody-mediated alloimmune hemolytic anemia (e.g., following a mismatched transfusion ) Paroxysmal nocturnal hemoglobinuria Mechanical shear-force associated lysis (Non-Immune-Mediated) (Option A) Microangiopathic hemolytic anemias (e.g., thrombotic thrombocytopenic purpura) Cardiac valvular disorders (e.g., prosthetic heart valves) March hemoglobinuria Membrane or hemoglobin disorder-associated lysis (Non-Immune-Mediated) (Option C) Sickle cell anemia Thalassemia Severe burns Exogenous toxic factors or infections (Option D) Falciparum malaria Clostridial sepsis Destruction of older fraction of G6PD-deficient red cells Favism Consequences: Acute anemia: rapid hemolysis of incompatible RBCs leads to significant anemia. Systemic effects: the activation of the complement system can have serious physiological effects, including: Disseminated intravascular coagulation (DIC): destruction of RBCs and release of free membranes activate the coagulation system. Acute kidney injury: release of Hb and complement activation can lead to renal failure. Shock-like symptoms: complement activation may cause smooth muscle constriction, increased small vessel permeability, and leukocyte activation. Laboratory findings in hemolytic disorders: Blood analysis: Hemoglobinemia (free Hb): Elevated in the plasma. Lactate Dehydrogenase (LDH): Marked increase due to RBC destruction. Bilirubin: Elevated indirect (unconjugated) bilirubin due to hemolysis. Haptoglobin: Decreased , as it",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Other Hemolytic Anemias"
    },
    {
      "q_no": 3,
      "question": "A 34-year-old woman presents with a 3-day history of confusion, fatigue, and diffuse petechial rash. Physical examination reveals mild jaundice and scattered petechiae over her arms and legs. Laboratory studies show the following results: Hemoglobin: 7.8 g/dL Platelet count: 22,000/µL Lactate dehydrogenase (LDH): Elevated Peripheral blood smear: Schistocytes present What is the most appropriate next step in the management of this patient?",
      "options": {
        "A": "Platelet transfusion",
        "B": "Plasmapheresis",
        "C": "High-dose intravenous immunoglobulin (IVIG)",
        "D": "Intravenous heparin"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) Plasmapheresis Explanation: This clinical scenario is suggestive of Thrombotic Thrombocytopenic Purpura (TTP), characterized by the pentad of microangiopathic hemolytic anemia, thrombocytopenia, neurological symptoms, renal dysfunction, and fever. In this case, the patient's confusion, fatigue, jaundice, petechial rash, low hemoglobin, low platelet count, elevated LDH, and presence of schistocytes on the peripheral blood smear all align with TTP. The most critical step in managing TTP is to perform plasmapheresis . Plasmapheresis helps to remove the circulating inhibitory antibodies against the von Willebrand factor-cleaving protease (ADAMTS13) , which is typically deficient or inhibited in TTP. Thrombotic Thrombocytopenic Purpura (TTP) TTP is a clinical syndrome characterized by the pentad of: Microangiopathic hemolytic anemia Thrombocytopenia (low platelet count) Neurological symptoms (e.g., confusion, headache, seizures) Fever Renal impairment (elevated creatinine and BUN) Etiology: Primary (Inherited): Genetic mutations in the ADAMTS13 gene, which encodes a von Willebrand factor (vWF) cleaving protease, leading to large vWF multimers and increased platelet aggregation. Secondary (Acquired): Autoantibodies against ADAMTS13, often triggered by infections (e.g., HIV, certain medications, and pregnancy), malignancies, or systemic conditions (e.g., lupus). Presentation: Fever Anemia Thrombocytopenia Renal failure: Decreased urine output, swelling (edema), and hypertension due to acute kidney injury. Neurological symptoms: Altered mental status, headaches, seizures, and focal neurological deficits. Investigations: Complete Blood Count (CBC): Low hemoglobin and low platelet count. Lactate Dehydrogenase (LDH): Elevated Haptoglobin: Decreased Coagulation Studies: Normal Peripheral Smear: Evidence of hemolysis, schistocytes (fragmented RBCs), and increased reticulocyte count. Urinalysis: Presence of hematuria and proteinuria. Renal Function Tests: Elevated serum creatinine and blood urea nitrogen (BUN). ADAMTS13 Activity and Inhibitor Testing: Confirmatory tests to assess for deficiency or inhibition of the ADAMTS13 enzyme. Management: Supportive Care: Hydration Blood Transfusions: For severe anemia, but cautious use due to potential exacerbation of hemolysis. Platelet Transfusions (Option A) : Generally avoided due to the risk of worsening thrombosis. Renal Support: Dialysis may be necessary in cases of acute renal failure. Specific Treatments: Plasmapheresis: First-line treatment for TTP; helps remove autoantibodies and replenish ADAMTS13 levels. Immunosuppressive therapy: Corticosteroids or rituximab may be considered in cases with underlying autoimmune conditions or refractory TTP.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Other Hemolytic Anemias"
    },
    {
      "q_no": 4,
      "question": "A 6-year-old boy presents with symptoms of fatigue, pallor, dysentery, abdominal pain, and reduced urine output. He has a recent history of consuming undercooked ground beef. Laboratory findings reveal elevated serum creatinine, elevated lactate dehydrogenase (LDH), low haptoglobin, and a peripheral blood smear shows characteristic findings. Considering the patient's clinical presentation and laboratory results, what is the definitive diagnostic method to identify the pathogen causing his condition?",
      "options": {
        "A": "Blood culture",
        "B": "Urinalysis",
        "C": "Stool culture",
        "D": "Serologic testing"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) Stool culture Explanation: The child's symptoms and recent consumption of undercooked ground beef suggest an infection with Escherichia coli O157, commonly associated with hemolytic uremic syndrome (HUS). Laboratory findings of elevated serum creatinine, elevated lactate dehydrogenase (LDH), low haptoglobin, and schistocytes on the blood smear support this diagnosis. The most definitive method for identifying this pathogen is a stool culture. Microangiopathic Hemolytic Anemia (MAHA) MAHA is characterized by hemolytic anemia due to the mechanical destruction of red blood cells (RBCs) as they pass through small blood vessels. This condition is often associated with: Thrombotic Thrombocytopenic Purpura (TTP) Hemolytic Uremic Syndrome (HUS) Disseminated Intravascular Coagulation (DIC) Mechanical cardiac valves Hemolytic Uremic Syndrome (HUS) HUS is a clinical syndrome characterized by the triad of: Microangiopathic hemolytic anemia Thrombocytopenia (low platelet count) Acute renal failure Etiology: The primary causes of HUS can be classified into two categories: 1. Typical HUS: Infectious agents: Most commonly",
      "image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxmedicine/Other_Hemolytic_Anemias_Q4_q.jpg",
      "explanation_image": null,
      "chapter_heading": "Other Hemolytic Anemias"
    },
    {
      "q_no": 5,
      "question": "A 70-year-old man with hypertension is prescribed α -methyldopa. After a few months of therapy, he develops mild anemia. His DAT is positive for IgG, and the eluate shows panagglutination. There is no evidence of renal dysfunction or hemoglobinuria. What is the most likely cause of his anemia?",
      "options": {
        "A": "Drug Adsorption",
        "B": "Immune Complex Mechanism",
        "C": "Autoimmune Mechanism",
        "D": "Non-Immunologic Protein Adsorption"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) Autoimmune Mechanism Explanation: The patient's anemia is likely due to an autoimmune mechanism induced by α -methyldopa , resulting in polyclonal IgG autoantibodies targeting RBC membrane antigens. Key findings include a positive DAT for IgG and panagglutination in the eluate, characteristic of this mechanism. Hemolysis is chronic and mild, with no renal dysfunction or hemoglobinuria, resembling idiopathic warm autoimmune hemolytic anemia (AIHA). Drug-immune hemolytic anemia Category Mechanism Clinical Presentation Example Drugs Drug Adsorption (Penicillin Type) (Option A) IgG antibodies bind to drug-coated RBCs leading to phagocytosis by splenic macrophages Gradual hemolysis over 7-10 days; splenic sequestration Penicillin Cephalosporin Tetracycline Tolbutamide Neoantigen/Immune Complex (Quinidine Type) (Option B) Antibodies bind to newly formed antigenic sites on RBCs, complement fixation leads to intravascular hemolysis Acute, severe hemolysis; hemoglobinuria; renal failure Quinidine Stibophen Sulfonamides Rifampicin Autoimmune Mechanism ( α -Methyldopa Type) (Option C) Polyclonal IgG autoantibodies attack RBC membrane components. Chronic, mild hemolysis; similar to idiopathic warm AIHA α -methyldopa Cladribine Fludarabine Mefenamic acid Procainamide Non-Immunologic Protein Adsorption (Option D) Proteins like fibrinogen, complement, or albumin adsorb to RBC membranes, not associated with RBC destruction Positive DAT; no hemolysis Cephalosporin Cisplatin Oxaliplatin Reference: Wintrobe’s Clinical Hematology, 14th edition, Page: 2462-2467.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Other Hemolytic Anemias"
    },
    {
      "q_no": 6,
      "question": "A 42-year-old woman with a history of rheumatoid arthritis presents with fatigue, pallor, and splenomegaly. Laboratory evaluation reveals anemia and a positive direct Coombs test. The DAT shows agglutination with both anti-IgG and anti-C3 reagents. Which of the following conditions is most likely associated with her presentation?",
      "options": {
        "A": "Cold-agglutinin disease",
        "B": "Warm-antibody autoimmune hemolytic anemia",
        "C": "Hapten type drug-induced immune hemolytic anemia",
        "D": "Paroxysmal cold hemoglobinuria"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) Warm-antibody autoimmune hemolytic anemia Explanation: The positive DAT showing agglutination with both anti-IgG and anti-C3 indicates the presence of both immunoglobulin and complement on RBCs, which is typical of Warm-antibody autoimmune hemolytic anemia . The patient's history of rheumatoid arthritis also predisposes her to develop autoimmune hemolytic anemia. Direct Antiglobulin Test (DAT) Demonstration of Antibody/Complement Binding: Confirm the presence of immunoglobulin or complement bound to the patient's red blood cells (RBCs). Utilize a broad-spectrum antiglobulin (Coombs) reagent containing antibodies against human immunoglobulin and complement components, primarily C3. Agglutination Observation: If agglutination occurs with the broad-spectrum reagent, proceed to specific tests: Use antisera reacting selectively with IgG ( γ Coombs). Use antisera reacting with C3 (non- γ Coombs). Major Patterns of Direct Antiglobulin Reaction Reaction Pattern Type of Immune Injury IgG Alone Warm-antibody autoimmune hemolytic anemia. Drug-immune hemolytic anemia: hapten drug adsorption type or autoantibody type. (Option C) Complement Alone Cold-agglutinin disease. (Option A) Paroxysmal cold hemoglobinuria. (Option D) Drug-immune hemolytic anemia: ternary complex type. Warm-antibody AHA with subthreshold IgG deposition. IgG Plus Complement Warm-antibody AHA. (Option B) Drug-immune hemolytic anemia: autoantibody type (rare) Laboratory Features of Immune-Mediated Hemolytic Anemia (AIHA) Parameter Key Features Hemoglobin & Hematocrit Ranges from normal (compensated hemolysis) to extremely low (severe RBC destruction) Elevated MCV. Reticulocyte Counts Typically elevated. May be low early due to marrow shutdown, infection, or parvovirus B19; hyperplastic marrow. Peripheral Blood Smear Hemolytic Anemia\" data-author=\"Barbaryan, Aram & Iyinagoro, Chioma & Nwankwo, Nwabundo & Ali, Alaa & Saba, Raya & Kwatra, Shawn & Hussain, Nasir & Uzoka, Cameron & Prueksaritanond, Suartcha & Mirrakhimov, Aibek.\" data-hash=\"9581\" data-license=\"CC BY \" data-source=\"https://www.researchgate.net/figure/Peripheral-blood-smear-shows-microsp herocytes-black-arrows-polychromasia-white_fig1_236941134\" data-tags=\"April2025\" height=\"231\" src=\"https://image.prepladder.com/notes/oNxXsSGnl6haqTyeMkJx1744391850.png\" width=\"300\" /> Shows: Reticulocytosis Polychromatophilia (white arrow) Macrocytosis (red arrow) Nucleated RBCs Spherocytes (black arrow) Agglutination Erythrophagocytosis. WBC & Platelet Counts WBCs may be elevated or low. Thrombocytopenia suggests Evans syndrome; possible immune-mediated cytopenias. Serum Tests Elevated unconjugated bilirubin (<5 mg/dL) Hemoglobinemia, hemoglobinuria. Low haptoglobin, increased urobilinogen, increased LDH. Possible false-positive syphilis tests. Reference: Wintrobe’s Clinical Hematology 14th edition Page: 2455. Williams Hematology 10th edition Page: 904.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Other Hemolytic Anemias"
    },
    {
      "q_no": 7,
      "question": "A 50-year-old woman presents with complaints of acrocyanosis and fatigue. She has a history of multiple myeloma and has been on lenalidomide therapy for the past 3 months. Laboratory tests reveal a hemoglobin level of 10.5 g/dL, a reticulocyte count of 5%, and a positive direct Coombs test. What is the most likely antibody type involved in this patient’s condition?",
      "options": {
        "A": "IgG",
        "B": "IgM",
        "C": "IgA",
        "D": "IgE"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) IgM Explanation: This patient is likely experiencing cold autoimmune hemolytic anemia (AIHA) associated with the use of lenalidomide , which can induce the formation of IgM antibodies . The presence of cold-induced symptoms such as acrocyanosis and the positive direct Coombs test indicates that IgM antibodies are involved in her hemolytic process. Warm AIHA vs cold AIHA Feature Warm AIHA (WAIHA) Cold AIHA (CAD) Type of Antibody Primarily IgG (Option A) Primarily IgM (Option B) Optimal Temperature 37°C 4°C–30°C Onset Abrupt and dramatic Gradual and chronic Etiology Idiopathic Secondary causes: Autoimmune diseases (e.g., SLE , scleroderma , RA ) Infections: Parvovirus B19, HIV, HCV, viral vaccines) Babesia Lymphoproliferative disorders (e.g., CLL, multiple myeloma) Chronic inflammatory disorders (e.g., IBD, thyroiditis including Hashimoto) Drug-induced cases (e.g., cefotetan, ceftriaxone , piperacillin, methyldopa , fludarabine) Idiopathic Secondary causes: Infections: (e.g., EBV , CMV) Mycoplasma Waldenströms disease lymphoma Drug-induced cases (e.g., lenalidomide ) Clinical features Abrupt symptoms, potentially severe anemia. Jaundice, splenomegaly. Elevated reticulocyte count, LDH Gradual onset Symptoms worsen with cold exposure. Hemoglobinuria. Acrocyanosis. Mechanism of Hemolysis The Fc portion of the IgG antibody bound to red cells is recognized by macrophage Fc receptors. Leading to erythrophagocytosis primarily in the spleen , liver, and bone marrow in an extravascular manner. IgM bound to red blood cells activates the complement cascade, leading to intravascular hemolysis , which can result in hemoglobinuria. Activated complement components, such as C3b, opsonize red blood cells, which are then destroyed by macrophages in an extravascular manner . Evans syndrome: It is characterized by the coexistence of warm autoimmune hemolytic anemia (AIHA) and autoimmune thrombocytopenia . IgA (Option C) can play a role in mucosal immunity, but it does not generally lead to hemolytic anemia. IgE (Option D) is primarily associated with allergic reactions and parasitic infections, not with hemolytic anemia. Reference: Harrison’s Principles of Internal Medicine 21st edition Page: 786, 787.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Other Hemolytic Anemias"
    },
    {
      "q_no": 8,
      "question": "A 6-year-old boy presents with hemoglobinuria and abdominal pain after playing outside in cold weather. He had a recent upper respiratory tract infection. Lab findings reveal hemoglobin of 4.2 g/dL, elevated LDH, and positive Donath-Landsteiner test. What is the pathophysiological mechanism of his condition?",
      "options": {
        "A": "IgG autoantibodies causing RBC lysis at warm temperatures",
        "B": "IgM autoantibodies causing RBC agglutination at cold temperatures",
        "C": "IgG auto-antibodies binding to RBCs at cold temperatures and causing lysis upon warming",
        "D": "Complement-mediated destruction of RBCs without any antibody involvement"
      },
      "correct_answer": "C",
      "explanation": "upon warming Correct Answer: C) IgG auto-antibodies binding to RBCs at cold temperatures and causing lysis upon warming. Explanation: The child’s hemoglobinuria and abdominal pain after cold exposure, combined with a recent upper respiratory infection and positive Donath-Landsteiner test, strongly indicate Paroxysmal Cold Hemoglobinuria . It is characterized by IgG autoantibodies that bind to red blood cells at cold temperatures and activate complement, leading to hemolysis when warmed to 37°C . Types of Autoimmune hemolytic anemia: Warm Autoimmune hemolytic anemia (IgG) Cold Autoimmune hemolytic anemia: Cold agglutinin syndrome (IgM) Paroxysmal Cold Hemoglobinuria (IgG) Paroxysmal Cold Hemoglobinuria (PCH) D-L Antibody Characteristics A hemolysin that binds to red blood cells (RBCs) at cold temperatures, fixing complement, and causes lysis when warmed. Typically IgG , directed against the P antigen on RBCs (a glycosphingolipid). \"Biphasic\" hemolysin: binds at 0°C–4°C and causes lysis when warmed to 37°C . Clinical Manifestations Sudden onset of fever, back/leg pain, and dark red-to-black hemoglobinuria after cold exposure. Symptoms may include cold-induced urticaria, Raynaud phenomenon, cyanosis, and, rarely, gangrene. Affects mostly children following viral infections (e.g., Mycoplasma , measles, mumps, influenza, EBV, varicella, parvo B19 etc.). Chronic PCH is common in late-stage or congenital syphilis , now rare due to syphilis treatment. Laboratory Features Severe intravascular hemolysis: hemoglobin <5 g/dL, hemoglobinuria, elevated LDH and bilirubin. Diagnostic hallmark : positive Donath-Landsteiner test It is an in-vitro test that detects anti-P antibodies in a patient's serum by incubating it with red blood cells at low temperatures, causing hemolysis upon warming if the antibodies are present. Direct Antiglobulin Test ( DAT) is usually positive for complement (C3) but not IgG. Management Supportive care : Transfusion of warmed blood if necessary. Steroids : Sometimes used in severe cases (though benefits are unproven). Avoidance of cold exposure : Crucial for chronic cases. Transfusion considerations : No need to search for rare P-negative blood units; standard P-positive blood is generally safe. IgG autoantibodies causing RBC lysis at warm temperatures (Option A) : PCH involves IgG autoantibodies binding to RBCs at cold temperatures, leading to lysis upon warming, not direct lysis at warm temperatures. IgM autoantibodies causing RBC agglutination at cold temperatures (Option B) : PCH specifically involves IgG antibodies, while IgM typically causes agglutination in conditions like cold agglutinin disease. Complement-mediated destruction of RBCs without any antibody involvement (Option D) : Complement activation in PCH occurs due to IgG antibody binding; therefore, antibody involvement is essential for the hemolytic process. Reference: Wintrobe’s Clinical Hematology, 14th edition, Page: 2446-2449.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Other Hemolytic Anemias"
    },
    {
      "q_no": 9,
      "question": "A 35-year-old male who works in a battery manufacturing company presents with fatigue, weakness, pallor, confusion, and a single seizure episode. He also reports numbness and tingling in his hands. A peripheral blood smear is ordered, which reveals characteristic findings. Based on the results of the blood smear, which of the following inclusions can be identified in the red blood cells?",
      "options": {
        "A": "Cabot rings",
        "B": "Howell-Jolly bodies",
        "C": "Pappenheimer bodies",
        "D": "Heinz bodies"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) Pappenheimer bodies Explanation: This clinical scenario suggests lead poisoning, particularly given the patient’s occupation in a battery manufacturing company and symptoms like fatigue, weakness, pallor, confusion, and neurological signs (numbness, tingling, and seizures). In lead poisoning, the toxic effect of lead interferes with heme synthesis, leading to sideroblastic anemia. In sideroblastic anemia, there is an accumulation of iron due to ineffective erythropoiesis, resulting in the formation of Pappenheimer bodies, which are small, iron-containing granules found within red blood cells. Inclusion Associated Conditions Cabot Rings (Option A ruled out) Megaloblastic anemia, sometimes seen in lead poisoning Howell-Jolly Bodies (Option B ruled out) Asplenia, post-splenectomy, certain hematologic disorders Pappenheimer Bodies Sideroblastic anemia, thalassemia, iron overload states, lead poisoning. Heinz Bodies (Option D ruled out) G6PD deficiency, oxidative stress, certain hemolytic anemias Basophilic Stippling Lead poisoning, thalassemia, heavy metal poisoning",
      "image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxmedicine/Other_Hemolytic_Anemias_Q9_q.jpg",
      "explanation_image": null,
      "chapter_heading": "Other Hemolytic Anemias"
    },
    {
      "q_no": 10,
      "question": "A 30-year-old male presents with jaundice, dark urine, fatigue, and pallor following recent travel to the Middle East, returning just two days ago. Routine blood tests indicate anemia with elevated bilirubin levels and decreased haptoglobin. A peripheral blood smear reveals specific findings. What is the most appropriate management for this condition?",
      "options": {
        "A": "Administer intravenous antibiotics.",
        "B": "Provide a blood transfusion",
        "C": "Avoid trigger factors and monitor",
        "D": "Initiate corticosteroid therapy"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) Avoid trigger factors and monitor. Explanation: This patient’s presentation is highly suggestive of G6PD deficiency, particularly after exposure to oxidative stressors such as certain foods (fava beans), infections, or medications. The patient's travel to the Middle East and recent onset of jaundice, dark urine, and pallor indicate hemolysis, likely triggered by fava bean ingestion (favism), a common oxidative stressor in endemic regions. The presence of bite cells and Heinz bodies in the peripheral blood smear indicates oxidative damage to red blood cells, which is characteristic of this condition. Given that there are no signs of severe disease, such as significant hemolysis or hemodynamic instability, the most appropriate management is a conservative approach. Educating the patient to avoid known triggers and closely monitoring their condition is essential. This strategy effectively minimizes the risk of further hemolytic episodes without unnecessary interventions like blood transfusions or corticosteroids. Investigations and Management in G6PD Deficiency Investigations: Clinical History: Exposure to known triggers. Blood Tests: Complete Blood Count (CBC): Indicates anemia and reticulocytosis. Serum Bilirubin: Elevated levels. Lactate Dehydrogenase (LDH): Elevated levels. Peripheral Blood Smear: May reveal bite cells and Heinz bodies. G6PD Enzyme Activity Test: A definitive test performed on a blood sample, ideally after hemolysis has resolved to avoid falsely normal results. Molecular Genetic Testing: Identifies specific mutations in the G6PD gene. Management: Management of G6PD deficiency aims to prevent",
      "image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxmedicine/Other_Hemolytic_Anemias_Q10_q.jpg",
      "explanation_image": null,
      "chapter_heading": "Other Hemolytic Anemias"
    },
    {
      "q_no": 11,
      "question": "A child suffering from malaria was treated with chloroquine and primaquine for several days but did not improve. The child has now developed new symptoms, including high-colored urine, severe abdominal pain, and shortness of breath. Which of the following conditions is most likely responsible for these symptoms?",
      "options": {
        "A": "Hypersensitivity reaction",
        "B": "Cinchonism",
        "C": "G6PD deficiency",
        "D": "Stevens-Johnson Syndrome"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) G6PD deficiency Explanation: The most likely condition responsible for the child's new symptoms is G6PD deficiency, a genetic disorder affecting the enzyme glucose-6-phosphate dehydrogenase, which protects red blood cells from oxidative stress. Certain medications, like chloroquine and primaquine, can trigger hemolysis in G6PD-deficient individuals. Symptoms such as dark-colored urine (hemoglobinuria), abdominal pain, and shortness of breath indicate a hemolytic crisis, where oxidative damage leads to the rapid destruction of red blood cells, explaining the worsening condition following drug treatment. G6PD Deficiency Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked genetic disorder characterized by a deficiency of the G6PD enzyme, which is essential for the hexose monophosphate shunt pathway. Etiology: G6PD catalyzes the conversion of glucose-6-phosphate to 6-phosphoglucono- δ -lactone, generating NADPH. NADPH is used to reduce oxidized glutathione (GSSG) to its active form (GSH), which neutralizes oxidative stress in RBCs. Without G6PD, this protective mechanism is impaired, making RBCs more vulnerable to damage under oxidative stress. Triggers of Hemolysis: Various drugs and environmental factors can precipitate hemolysis, including: Drugs: Antimalarials: Primaquine, chloroquine Sulfonamides: Sulfamethoxazole, sulfasalazine Antibiotics: Nitrofurantoin, dapsone Analgesics: High-dose aspirin, phenacetin Chemotherapeutics: Daunorubicin, doxorubicin Others: Methylene blue, rasburicase, certain NSAIDs Other Causes: Fava beans (favism) Infections: Certain viral and bacterial infections Environmental Factors: Exposure to oxidizing agents, such as naphthalene Pathogenesis: G6PD deficiency → Reduced glutathione levels decrease → Oxidative stress → Hemolysis → Acute hemolytic anemia Clinical Features: Acute Hemolytic Anemia: Fatigue Pallor Jaundice Dark urine Splenomegaly Symptoms During Hemolytic Crises: Shortness of breath Rapid heart rate Abdominal pain Hypersensitivity (Option A) , also known as an exaggerated immune reaction, is a condition where the immune system responds abnormally to an antigen, leading to harmful and undesirable effects on the body. It is not associated with dark-coloured urine. Cinchonism (Option B) refers to a group of reversible side effects caused by quinine, which can include symptoms like tinnitus, hearing loss, headache, nausea, vomiting, feelings of discomfort or unease, and vision problems. Stevens-Johnon syndrome (Option D) and toxic epidermal necrolysis are severe, uncommon skin conditions that can be life-threatening. These reactions involve the shedding of skin and, in some cases, mucous membranes, along with systemic symptoms.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Other Hemolytic Anemias"
    },
    {
      "q_no": 12,
      "question": "A 12-year-old boy from southern India presents with recurrent severe joint pain, fatigue, and jaundice. Lab tests show hemoglobin of 7 g/dL, high reticulocyte count, and sickle-shaped erythrocytes on a blood smear. Which of the following is not a pathophysiology consistent with this disorder?",
      "options": {
        "A": "HbS polymerization causes sickling and hemolysis, releasing cell-free hemoglobin.",
        "B": "Vaso-occlusion from sickle cell and inflammatory cell aggregation, leads to ischemia.",
        "C": "Endothelial dysfunction due to depletion of nitric oxide and the generation of free radicals.",
        "D": "Impaired erythropoietin production leading to inadequate bone marrow response"
      },
      "correct_answer": "D",
      "explanation": "response Correct Answer: D) Impaired erythropoietin production leading to inadequate bone marrow response. cells point towards a diagnosis of Sickle Cell Anemia. Impaired erythropoietin production does not fit the pathophysiological mechanisms underlying sickle cell anemia. Epidemiology of Sickle cell anemia: First case of sickle hemoglobin in India: Found in tribal populations in the Nilgiri hills, South India,1952. Sickle cell trait appears to reduce the incidence of malaria. Prevalence of sickle cell trait is higher in areas where malaria is endemic. Trait is prevalent in southern and central India. Pathophysiology of Sickle cell anemia: 1. HbS Polymerisation: (Option A) A single-nucleotide polymorphism in the β -globin gene results in the substitution of valine for glutamic acid at the sixth position in the β -globin chain. This mutation leads to the formation of mutated hemoglobin (HbS). After deoxygenation, HbS molecules polymerize to form bundles. These polymer bundles cause erythrocytes to adopt a sickle shape and also promote hemolysis of erythrocytes, releasing cell-free Hb into circulation. 2. Vaso-occlusion: (Option B) Sickled erythrocytes impair blood flow and aggregate with neutrophils, platelets, and endothelial cells, causing stasis. Leads to ischemia-reperfusion (I-R) injury. 3. Endothelial Dysfunction: (Option C) Oxygenated Hb (Fe² I ) depletes endothelial nitric oxide (NO), forming nitrate (NO II ) and methemoglobin (Fe³ I ). Free radicals are generated by NADPH oxidase, xanthine oxidase (XO), and uncoupled endothelial NO synthase (eNOS) contributing to endothelial damage and dysfunction. Methemoglobin (Fe³ I ) breaks down, releasing cell-free heme, which is a major erythrocyte damage-associated molecular pattern (DAMP). 4. Sterile Inflammation: Cell-free heme or ischemia-reperfusion injury triggers sterile inflammation by: Generating reactive oxygen species (ROS). Activating Toll-like receptor 4 (TLR4). Inducing neutrophil extracellular traps (NETs). Releasing DAMPs, DNA, and other unidentified factors. This activates the inflammasome pathway, releasing IL-1 β . Sterile inflammation enhances the adhesiveness of neutrophils, platelets, and endothelial cells. This creates a cycle that promotes further vaso-occlusion.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Other Hemolytic Anemias"
    },
    {
      "q_no": 13,
      "question": "A 25-year-old woman presents to the hospital with yellowish discoloration of the skin for a few days. She has no severe symptoms and the discoloration was gradual in onset. On blood analysis, he is found to have raised unconjugated bilirubin levels. Which of the following is not a cause of this condition?",
      "options": {
        "A": "Direct damage to erythrocytes",
        "B": "Shear stress from microangiopathy",
        "C": "Immune-mediated hemolysis",
        "D": "Destruction of older fraction of G6PD-deficient red cells"
      },
      "correct_answer": "D",
      "explanation": "Correct Answer: D) Destruction of older fraction of G6PD-deficient red cells Explanation: The diagnosis here points to extravascular hemolysis , however, the destruction of the older fraction of G6PD-deficient red cells is found in conditions like favism which causes intravascular hemolysis . Mechanism and site of extravascular hemolysis: The autoantibodies in autoimmune hemolytic anemia, consider the erythrocytes \"foreign” and the decreased deformability in conditions like sickle cell anemia or hereditary spherocytosis leads to the destruction of the RBCs . This destruction primarily occurs in the mononuclear phagocyte system, particularly in the spleen and liver . Potential causes: Direct oxidative or structural damage to erythrocytes. (Option A ruled out) Fragmentation due to shear stress from microangiopathy, hemangiosarcoma, or disseminated intravascular coagulopathy (DIC). (Option B ruled out) Immune-mediated hemolysis ( Eg: warm AIHA) (Option C ruled out) and hemotropic parasites (e.g., Plasmodium). Increased senescence of erythrocytes. Differences Between Extravascular Hemolysis and Intravascular Hemolysis Feature Extravascular Hemolysis Intravascular Hemolysis Site of Hemolysis Occurs in the spleen, liver, and reticuloendothelial system. Occurs within the blood vessels. Mechanism Destruction of RBCs by macrophages (phagocytosis). RBCs lyse due to mechanical injury, complement activation, or toxins. Serum Haptoglobin Decreased or slightly reduced. Significantly decreased or absent. Hemoglobinemia Absent. Present due to free hemoglobin in plasma. Hemoglobinuria Absent. Present (causes dark-colored urine). Urine Hemosiderin Absent. Present (due to renal tubular uptake of hemoglobin). LDH Levels Mildly increased. Markedly increased. Unconjugated Bilirubin Elevated (due to breakdown of heme in macrophages). Elevated (from released heme). Peripheral Blood Smear Spherocytes or target cells may be seen. Schistocytes (fragmented RBCs) are typical. Reticulocyte Count Increased. Increased (if bone marrow compensates). Associated Conditions Hereditary spherocytosis, autoimmune hemolytic anemia (warm type). Paroxysmal nocturnal hemoglobinuria, mechanical hemolysis (e.g., prosthetic valves), cold AIHA, G6PD deficiency. Splenomegaly Common (due to increased RBC destruction). Rare. Other features - Coombs test is positive in autoimmune hemolysis. - Splenectomy may be beneficial in some cases. - Hemosiderinuria indicates chronic intravascular hemolysis. - Schistocytes are a hallmark of microangiopathic hemolysis. Reference: www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/intravascular-hemolysis www.sciencedirect.com/topics/medicine-and-dentistry/hemolysis",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Other Hemolytic Anemias"
    },
    {
      "q_no": 14,
      "question": "A 30-year-old male presents with fatigue, jaundice, and dark urine. Laboratory tests reveal elevated indirect bilirubin levels and a hemoglobin level of 8 g/dL. A peripheral blood smear shows spherocytes. Which of the following classifications best describes this patient's condition?",
      "options": {
        "A": "Acquired hemolytic anemia due to autoimmune hemolysis",
        "B": "Inherited hemolytic anemia due to enzyme abnormalities",
        "C": "Acquired hemolytic anemia due to mechanical destruction",
        "D": "Inherited hemolytic anemia due to membrane-cytoskeletal defects"
      },
      "correct_answer": "D",
      "explanation": "Correct Answer: D) Inherited hemolytic anemia due to membrane-cytoskeletal defects Explanation: The diagnosis here is hereditary spherocytosis, an inherited condition, characterized by spherocytes due to abnormalities in the membrane-cytoskeleton complex of red blood cells. This falls under inherited hemolytic anemias due to membrane-cytoskeletal defects. Hemolytic anemias are caused as a result of the destruction of the red blood cells in the body with normal bone marrow. They can be classified based on many factors: Based on etiology: inherited or acquired. Based on clinical presentation: acute or chronic. Based on the site of hemolysis: intravascular or extravascular. Based on the mechanism of the disease: intracorpuscular causes or extracorpuscular causes. Based on the etiology and mechanism of the disease, hemolytic anemias are classified as follows: Intracorpuscular defects Extracorpuscular defects Inherited Hemoglobinopathies Eg: Sickle cell disease Enzymopathies Eg: G6PD Deficiency Membrane-cytoskeletal defects Eg: Hereditary spherocytosis Familial (atypical) hemolytic uremic syndrome Acquired Paroxysmal nocturnal hemoglobinuria Mechanical destruction (microangiopathies) Toxic agents Drugs Infectious Autoimmune Hemolytic anemias can further be divided as per the etiology as: Inherited hemolytic anemia: Hemolytic anemias due to abnormalities of the membrane-cytoskeleton complex: Hereditary spherocytosis Hereditary elliptocytosis Hemolytic anemia due to channelopathies Due to enzyme abnormalities: Abnormalities of the glycolic pathway: pyruvate kinase deficiency and other glycolytic enzyme abnormalities Abnormalities of redox metabolism: glucose-6-phosphate dehydrogenase deficiency and other abnormalities Pyrimidine 5’-nucleotide deficiency Due to familial (atypical) hemolytic-uremic syndrome Acquired hemolytic anemia: Due to the mechanical destruction of red cells Infections like Malaria Shiga-toxin producing E-coli Clostridium perfringens Immune hemolytic anemias Autoimmune hemolytic anemia, warm type Paroxysmal cold hemoglobinuria Cold agglutination disease Hemolytic anemia from toxic agents and drugs: Hyperbaric oxygen Nitrates Chlorates Methylene blue Dapsone Cisplatin Aromatic compounds Paroxysmal nocturnal hemoglobinuria (PNH) Bone marrow failure and the relationship between PNH and aplastic anemia Learning Objective: General features of hemolytic anemias: Clinical features Jaundice Pallor Splenomegaly Bossing of the skull in severe congenital cases Laboratory findings Normal to severely low hemoglobin Increased MCV, and MCH Increased reticulocytes Increased bilirubin (unconjugated) Increased LDH (up to 10x normal with intravascular hemolysis) Reduced to absent haptoglobin (if intravascular hemolysis is also present) Reference: Harrison’s Principles of Internal Medicine, 21st edition, Page: 776, 778-790.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Other Hemolytic Anemias"
    },
    {
      "q_no": 15,
      "question": "A 6-year-old girl with a confirmed diagnosis of sickle cell anemia presents to the emergency department with severe fatigue, pallor, and a recent history of frequent painful episodes. Her mother reports that she has experienced a headache and dizziness over the past two days. The physician suspects severe anemia and potential complications. What is the most appropriate initial management, considering her clinical presentation?",
      "options": {
        "A": "Initiate gene therapy immediately",
        "B": "Administer hydroxyurea",
        "C": "Start transfusion therapy",
        "D": "Schedule a stem cell transplant consultation"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) Start transfusion therapy Explanation: The scenario points to severe symptomatic anemia, which is an indication of transfusion therapy . It is also indicated for the treatment and prevention of stroke, acute chest syndrome with hypoxia or multiple lobe involvement. Other treatment modalities of sickle-cell disease: Transfusion Therapy Mechanism of action: Increases hemoglobin levels. Reduces the risk of complications such as stroke. Use: Indicated for severe symptomatic anemia. For stroke prevention. Acute chest syndrome with hypoxia or multiple lobe involvement. In pregnancy, if there is a history of complications or fetal loss. Dosage: Varies based on the clinical scenario. For example: automated red cell exchange is preferred in acute situations. Important details: Avoided during acute pain episodes unless indicated. Extended antigen profiling is recommended before the first transfusion. Stem Cell Transplantation (Option D ruled out) Mechanism of action: Replaces diseased bone marrow with healthy, HLA-matched stem cells. Use: Considered for patients with suitable donors. Important details: Event-free survival exceeds 95% with HLA-identical related donors. Only about 15% of patients have matched donors. Haploidentical transplants are improving outcomes with newer approaches. Gene Therapy (Option A ruled out) Mechanism of action: Modified autologous hematopoietic CD34+ stem cells are used to produce antisickling globin or increase HbF levels. Use: It is a potentially curative approach for sickle cell disease. Important details: Casgevy and Lyfgenia are the FDA approved gene therapies used to manage sickle cell anemia. Ongoing clinical trials show promising results. Long-term safety and efficacy are still under evaluation. Preventive Measures Screening: Cord blood screening for sickle cell disease is necessary for early intervention. Prophylactic measures: Transcranial Doppler screening. Prophylactic penicillin for children. Vaccination against pneumococcal infections. These are the mainstays in preventing invasive pneumococcal infection and stroke. Antenatal counselling: Screen women planning pregnancy for hemoglobin disorders. Test partners of individuals with sickle cell traits. Treatment of complications: Vaso-occlusive crises are treated with Aggressive rehydration. Oxygen therapy. Effective pain management, often necessitating opioid analgesics, along with antibiotics. Administer hydroxyurea (Option B): This is the first and most commonly used treatment modality for sickle cell anemia patients of all ages. However, in this case, the patient has symptoms of acute severe anemia, and hence, the preferred treatment is transfusion. Reference: Harrison’s Principles of Internal Medicine, 21st edition, Page: 761. www.fda.gov/news-events/press-ann ouncements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease#:~:text=Casgevy%2C%20a%20cell",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Other Hemolytic Anemias"
    },
    {
      "q_no": 16,
      "question": "A 19-year-old male with a known history of sickle cell anemia presents to the clinic with recurrent painful crises over the past month. He has been on hydroxyurea for the last year, which has provided some relief, but his symptoms remain frequent and debilitating. Which of the following treatments should the physician consider adding to help reduce the frequency of his painful crises?",
      "options": {
        "A": "Voxelotor",
        "B": "Crizanlizumab",
        "C": "Increase the dose of hydroxyurea",
        "D": "L-Glutamine"
      },
      "correct_answer": "A",
      "explanation": "Correct Answer: A) Voxelotor Explanation: Here, the symptoms of the patient are not alleviated by hydroxy urea alone and hence, the next best step is to add voxelotor to the regimen which has an additive effect on hydroxyurea , especially in the case of adults. Pharmacological Treatments for Sickle Cell Anemia: Hydroxyurea Mechanism of Action: Increases fetal hemoglobin (HbF) levels. Reduces sickle hemoglobin (HbS) polymerization. Use: Standard care for all patients with sickle cell anemia and HbS- β 0 thalassemia. It is used for patients of all ages regardless of the symptoms. Dosage: Start at ~20 mg/kg for children. Titrate to the maximum tolerated dose based on blood counts. Important Details: Reduces pain crises and acute chest syndrome by ~50%. Treatment is initiated in the first year of life. Long-term use has decreased mortality. Increases hemoglobin by about 1 gm/dL. Voxelotor Mechanism of Action: Increases hemoglobin's affinity for oxygen. Reduces sickling and hemolysis. Use: Improves hemoglobin levels in sickle cell disease patients. It is added with hydroxyurea for additive results especially in adults when the symptoms are not sufficiently reduced by hydroxyurea alone. Dosage: 1500 mg daily. Important Details: Associated with a 1 g/dL increase in hemoglobin in 59% of patients. Long-term benefits and safety are under investigation. Crizanlizumab (Option B) Mechanism of Action: Blocks P-selectin to prevent sickle cell-endothelial adhesion. Use: Reduces frequency of painful crises. Can be added with hydroxyurea and Voxelotor for additive results when the vaso-occlusive complications still continue with these medications at the right doses. Dosage: Administer intravenously once a month. Important Details: Associated with a ~45% reduction in acute painful episodes. No significant effect on hemolysis is observed. L-Glutamine (Option D) Mechanism of Action: Reduces oxidative stress in sickle erythrocytes. Use: Helps manage pain episodes. Dosage: Specific dosage determined in clinical trials. Important Details: Shows a 25% reduction in painful episodes. Associated with a 33% decrease in hospitalizations compared to placebo. Increase the dose of hydroxyurea (Option C): The failure of the maximum tolerated/safe dose to control the symptoms is when other medications are added. Hence, increasing the dose of hydroxyurea is not an option as it may cause toxicity as well. Reference: Harrison’s Principles of Internal Medicine, 21st edition, Page: 760, 761.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Other Hemolytic Anemias"
    },
    {
      "q_no": 17,
      "question": "A 6-year-old boy is brought to the emergency department with severe pain in his hands and feet, with several episodes of pain over the past year and occasional experiences of fatigue. His hand appears as follows: A blood film shows the presence of sickle cells and target cells. Which of the following is the investigation of choice for the diagnosis of this child’s condition?",
      "options": {
        "A": "X-ray spine",
        "B": "High-performance liquid chromatography",
        "C": "HbS detection using a reducing agent",
        "D": "Parental genetic testing"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) High-performance liquid chromatography Explanation: The probable diagnosis here points to sickle cell disease because of the presence of sickle cells in the peripheral smear and the clinical symptoms of dactylitis (image), body pain, and fatigue. High-performance liquid chromatography differentiates hemoglobin fractions due to their varying interactions with the stationary phase which is the most commonly used method for the diagnosis. Investigative findings in sickle cell disease: Complete blood count shows: Reduced hemoglobin level. Low hematocrit and red blood cells. Reticulocyte count: reticulocytosis is present, indicating increased red blood cell production in response to hemolysis and tissue hypoxia. Blood film analysis shows: Presence of sickle cells. Target cells. Features indicating hyposplenism (common from a young age). High-performance liquid chromatography (HPLC): HPLC differentiates hemoglobin fractions due to their varying interactions with the stationary phase. It identifies different types of hemoglobin by analyzing the retention time and the shape of the resulting peaks It can detect most kinds of sickle cell disease. It is an automated procedure. It detects Hb F, Hb A2, Hb S, Hb C, Hb Barts, and other Hb variants. Radiography: X-ray of the spine shows “fish",
      "image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxmedicine/Other_Hemolytic_Anemias_Q17_q.png",
      "explanation_image": null,
      "chapter_heading": "Other Hemolytic Anemias"
    },
    {
      "q_no": 18,
      "question": "A 22-year-old male presents for evaluation after experiencing fatigue and occasional pain during a recent hiking trip. He reports that his family has a history of sickle cell disease. A laboratory evaluation reveals that he carries sickle cell trait. Which of the following statements best describes this patient's condition?",
      "options": {
        "A": "He has two copies of the hemoglobin S gene.",
        "B": "He is likely to experience frequent vaso-occlusive crisis.",
        "C": "He has HbS, HbF, and HbA2 present, while HbA is absent.",
        "D": "His symptoms may arise from hypoxia, dehydration, or extreme temperatures"
      },
      "correct_answer": "D",
      "explanation": "Correct Answer: D) His symptoms may arise from hypoxia, dehydration, or extreme temperatures. conditions that favor sickling, such as hypoxia, dehydration, or extreme temperatures. Sickle Cell Trait Sickle Cell Disease Genetic Profile One copy of the hemoglobin S gene Two copies of the hemoglobin S gene (Option A) Hemoglobin electrophoresis HbA, HbS present HbS, HbF, HbA2 present. HbA absent. (Option C) Symptoms Usually asymptomatic Broad clinical manifestations (eg, generalized pain and fatigue) due to vaso-occlusive crisis, hemolysis, and infectious exacerbations. (Option B) Onset of symptoms Exposure to conditions that favor sickling, including: Severe hypoxia Dehydration Increased sympathetic outflow Hypothermia Hyperthermia High 2,3-DPG levels Release of inflammatory cells. - Reference: Harrison’s Principles of Internal Medicine, 21st Edition, Page: 757. https://www.nhlbi.nih.gov/health/sickle-cell-disease/sickle-cell-trait# https://www.ncbi.nlm.nih.gov/books/NBK537130/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Other Hemolytic Anemias"
    },
    {
      "q_no": 19,
      "question": "Which of the following is not a characteristic special finding of sickle cell anemia?",
      "options": {
        "A": "Presence of Heinz bodies.",
        "B": "Elongated, crescent-shaped red blood cells on peripheral smear.",
        "C": "Presence of target cells due to splenic sequestration.",
        "D": "Crew-cut appearance on skull X-ray due to extramedullary hematopoiesis."
      },
      "correct_answer": "A",
      "explanation": "Correct Answer: A) Presence of Heinz bodies. Explanation: Heinz bodies indicate oxidative injury to red blood cells, commonly seen in conditions like G6PD deficiency . While oxidative stress may occur in sickle cell anemia, Heinz bodies are not a typical feature of this condition. Special Features of Sickle Cell Anemia: Crew-cut/ Hair-on-end appearance: (Option D) A characteristic radiographic feature seen in chronic hemolysis, commonly in patients with thalassemia and sickle cell anemia. Hallmark of extramedullary hematopoiesis. This appearance is due to the thickening of the vertical trabeculae between the inner and outer tables of the skull because of excessive bone marrow hyperplasia. Marked expansion of marrow leading to bone resorption and new bone formation. RBC Shape: (Option B) Sickle-shaped RBC: Elongated, crescent-shaped red blood cells with pointed ends. Schistocytes: Seen due to splenic sequestration. Presence of target cells (Option C) : Due to altered red cell membrane structure and splenic sequestration, often seen in sickle cell disease.",
      "image": null,
      "explanation_image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxmedicine/Other_Hemolytic_Anemias_Q19_exp.jpg",
      "chapter_heading": "Other Hemolytic Anemias"
    },
    {
      "q_no": 20,
      "question": "A 15-year-old male is diagnosed with sickle cell anemia. His parents are concerned and want to know the potential complications associated with the disease. Which of the following complications is most commonly associated with sickle cell anemia?",
      "options": {
        "A": "Osteonecrosis, typically affecting the hips bilaterally.",
        "B": "Acute Chest Syndrome, marked by cough and chest pain.",
        "C": "Vaso-occlusive crises, leading to severe unprovoked pain",
        "D": "Leg ulcers, which can become deep and difficult to manage."
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) Vaso-occlusive crises, leading to severe unprovoked pain. Explanation: Vaso-occlusive crises are the most frequent acute complication in sickle cell anemia, often leading to significant pain and necessitating medical intervention. Complications of sickle cell disease can be grouped into: Acute Painful Episodes (Vaso-Occlusive Crises): (Option C) Characterized by unprovoked, severe pain, often symmetrical, and typically requiring strong opioids. The most common acute event in sickle cell disease, with varying frequency. Pain may last days to weeks. Sudden death after admission for acute pain episodes can occur, often with unknown causes (possible arrhythmias or pulmonary embolism). Acute Chest Syndrome: (Option B) Second most common acute event, occurring in over 50% of patients. Symptoms include chest pain, cough, fever, hypoxia, and pulmonary infiltrates on x-ray. Can be mild in children (e.g., due to viral infections) or severe with multiple lobes affected. Thrombocytopenia, leukocytosis, and rapid anemia suggest severe complications like acute respiratory distress syndrome (ARDS) and multiorgan failure. Osteonecrosis: (Option A) Affects around 50% of patients with sickle cell anemia, often involving the hips bilaterally. Chronic pain, that can progress to severe disability; MRI detects early stages, while x-rays are less sensitive. Leg ulcer: (Option D) Frequently seen in sickle cell anemia. Ulcers range from small and superficial to deep, covering most of the lower leg. Often painful, and difficult to treat if recurrent, long-standing and large ulcer. Other Complications: Priapism Stroke and silent infarction Gallstones/Surgery Hepatic disease Nephropathy Lung/pulmonary hypertension Retinopathy Aplastic crisis: Caused by parvovirus B19 infection Multiorgan failure Reference: Harrison’s Principles of Internal Medicine, 21st Edition, Page: 758, 759, 760. Davidson’s Principles and Practice of Medicine, 24th Edition, Page: 952.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Other Hemolytic Anemias"
    },
    {
      "q_no": 21,
      "question": "A 7-year-old African American boy has recurrent leg pain, fatigue, and occasional yellowing of eyes. Examination shows scleral icterus and splenomegaly. Labs reveal anemia with elevated reticulocytes, and the blood smear shows sickle-shaped red cells. Which of the following features is not consistent with his condition?",
      "options": {
        "A": "Increased susceptibility to infections due to splenic dysfunction.",
        "B": "Severe abdominal pain due to splenic dysfunction, resembling pancreatitis.",
        "C": "Recurrent bone pain leads to avascular necrosis (AVN), which is best assessed by MRI.",
        "D": "Painful swelling of hands and feet (dactylitis) from blood vessel blockage."
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) Severe abdominal pain due to splenic dysfunction, resembling pancreatitis. jaundice, and characteristic sickle cells on the blood smear. While abdominal pain can occur in sickle cell disease, it is typically associated with vaso-occlusive crises rather than direct splenic dysfunction. Clinical Features of Sickle Cell Anemia: Fetal hemoglobin (HbF) persists up to 6 months of life, with a residual amount (<1%) in adulthood. In regions without newborn screening, affected children are typically identified after 6 months of age. Sickle cell disease does not predispose to neonatal jaundice. Fever: (Option A) Autosplenectomy, along with reduced splenic function, increases susceptibility to infections from encapsulated bacteria: Pneumococci Meningococci H. influenzae Acute abdominal pain: (Option B) Occurs during vaso-occlusion or distal tissue ischemia. Constant, non-positional abdominal pain, not aggravated by food, was located in the left upper quadrant and epigastric area. Misdiagnosed as acute pancreatitis or splenic abscess. Bone pain: (Option C) Sickled cells can obstruct blood flow in blood vessels supplying the bones, leading to inadequate oxygen delivery. Lack of oxygen to bone tissue can cause cell death, leading to a complication called avascular necrosis (AVN). IOC for avascular necrosis: MRI Dactylitis/Hand and foot syndrome: (Option D) Refers to painful, symmetric swelling of the hands and feet in children with sickle cell disease. It occurs due to infarction of the metacarpals, metatarsals, and phalanges caused by sickled erythrocytes blocking blood vessels. Swelling is followed by hyperemia and subperiosteal new bone formation, visible on radiographs 10-14 days after the swelling subsides. Reference: Harrison’s Principles of Internal Medicine, 21st Edition, Page: 758. https://pmc.ncbi.nlm.nih.gov/articles/PMC9759007/ https://pubmed.ncbi.nlm.nih.gov/3358402/ https://www.ajol.info/index.php/nhp/article/view/119295# https://pmc.ncbi.nlm.nih.gov/articles/PMC6952462/# https://www.cdc.gov/sickle-cell/complications/avascular-necrosis.html https://www.ncbi.nlm.nih.gov/books/NBK537007/# https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621170/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Other Hemolytic Anemias"
    }
  ]
}
